scPharmaceuticals Inc. (SCPH)
$5.67+0.00%Close
BUYBULL · day 20
Key stats
- Market cap
- $302M
- Beta
- 0.30
- P/E (TTM)
- -2.97
- 1W
- +0.18%
- 1M
- +0.89%
- vs SPY 1W
- +0.32%
- vs SPY 1M
- -1.62%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 38
- VALUE
- 27
- GROWTH
- 12
- GARP
- 81
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-202.2%
REV YoY-
ROE-337.0%
EPS YoY-
ROA-79.2%
GROSS69
OP-178
NET-234
[VALUATION]
P/E TTM-2.97
P/E FWD9.65
SECTOR PE20.34
INDUSTRY PE13.84
P/B18.95
P/FCF-
EV/EBITDA-3.60
EV/EBIT-
PEG0.15
FCF YIELD-
RISK
INT COV-
D/E395.59
ALTMAN Z-
CURR RATIO7.12
ND/EBITDA-
BETA0.30
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on SCPH?
- LOPJLB’s latest quantitative signal on scPharmaceuticals Inc. (SCPH) is BUY in a BULL regime. Signals are updated daily.
- What market regime is SCPH in?
- scPharmaceuticals Inc. (SCPH) is currently classified in the BULL HMM market regime on LOPJLB.
- What does scPharmaceuticals Inc. (SCPH) do?
- scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treati…